SIRT1 and chronic myelogenous leukemia, BCR-ABL1 positive: Moreover, SIRT1 rendered HSCs vulnerable to stepwise mutation development in CML, while SIRT1 inhibition strengthened DNA repair and improved the sensitivity of leukemic stem cells (LSCs) to imatinib.385 The evidence of the SIRT family affecting hematologic malignancies is relatively limited.